Oculis Holding AG (Nasdaq: OCS) – a global biopharmaceutical company with the mission to save sight and improve eye care – is proud to announce the launch of its new office in Boston, Massachusetts. This milestone marks a major step forward in Oculis’ US presence and is a testament to its commitment to becoming an active player in the American market. With this new office, Oculis is ready to execute its ambitious strategy and improve the lives of those with eye care issues.
Oculis is thrilled to announce the opening of their new Boston office, situated in the bustling hub of the global life sciences industry. This strategic location will enable the company to fully support their US operations as they gear up for key clinical and late-stage data milestones in 2021, including results from their Phase 3 DIAMOND and OPTIMIZE studies of OCS-01 in DME and Inflammation and Pain following cataract surgery.
Oculis is thrilled to announce the expansion of its presence in the US, and the strengthening of its finance and development team with the hiring of Dr. Fang Li as Senior Vice President, Regulatory Affairs. With over 25 years of drug development experience and 20 years in regulatory affairs, Dr. Li has a proven track record in gaining product approvals from the US and other regions.
She has been involved in many successful FDA drug approvals within ophthalmology, including Jetrea, Lotemax Ointment, Systane Complete, Beovu, Lotemax Gel, Besivance, and Vyzulta. Oculis is excited to have Dr. Li on board and looks forward to her expertise in health authority interactions, FDA advisory committee meetings, and building and leading regulatory teams.
Riad Sherif, MD, CEO of Oculis, is delighted to announce the opening of their US headquarters in Boston – a city renowned for its innovation and world-class medical centers. To further strengthen their global development team, Oculis has also welcomed Dr Fang Li to their ranks.
This new chapter for Oculis is a major milestone and Sherif is looking forward to taking advantage of all the talent and partnerships available in the area, as well as contributing to the local biotech ecosystem.
Oculis is a biopharmaceutical powerhouse committed to restoring and improving eye care around the globe. Its diverse pipeline consists of groundbreaking, innovative treatments for various eye conditions, including diabetic macular edema (OCS-01), dry eye disease (OCS-02), and acute optic neuritis and other neuro-ophthalmic disorders (OCS-05).
With a strong leadership team and the backing of prominent healthcare investors, Oculis is well-positioned to bring life-changing treatments to those in need. Headquartered in Switzerland, with operations in the US, Europe, and China, Oculis is set to make a lasting impact on global eye care.